Updated on 12 October 2015
China is expected to become the world's second largest pharmaceutical market after the US by 2020
Singapore: Medidata, a global provider of cloud-based solutions for clinical research in life science industry, recently collaborated with Japan Pharmaceutical Manufacturers Association (JPMA) to streamline clinical trial costs across Japan. The idea is to optimize clinical trial costs in Japan's clinical trial landscape.
Medidata's cloud platform of innovative technology and data analytics is to support life science organizations to conduct their clinical trials at lesser risks and costs. Mr Motohide Nishi, vice president of research and development, APAC region, Medidata, highlights the significance of cloud based solutions and mobile health technology in managing clinical trials across different regions and different patient groups.
What role can mobile health technology play in enhancing the clinical trial management in Asia?
As the drug development market continues to expand globally, more clinical trials are being conducted across Asia. China alone is expected to become the world's second largest pharmaceutical market after the US by 2020, with spend projected to reach $260 billion according to Journal of Pharmaceutical Policy and Practice.
However, with this increase in activity comes increased costs and the need for additional resources. That's why leading life sciences organizations in Asia are beginning to recognize the potential new mobile technologies have to help bring novel and important medicines to patients faster, safer and more efficiently, and are embarking on the early stages of exploring these devices in clinical development. mHealth technologies have the capability to collect powerful data that can reveal what is and what isn't working in a trial, providing insight needed to make changes earlier, saving time, money and resources. Additionally, mobile devices help reduce the burden on those participating in studies by streamlining routine procedures, eliminating unnecessary ones and reducing clinical trial site visits.